|
1.
|
|
14 p, 1.7 MB |
Immunogenic dynamics and SARS-CoV-2 variant neutralisation of the heterologous ChAdOx1-S/BNT162b2 vaccination : Secondary analysis of the randomised CombiVacS study
/
García-Pérez, Javier (Instituto de Salud Carlos III) ;
González-Pérez, María (Instituto de Salud Carlos III) ;
Castillo de la Osa, María (Instituto de Salud Carlos III) ;
Borobia, Alberto M. (Universidad Autónoma de Madrid) ;
Castaño, Luis (Hospital Universitario Cruces) ;
Bertrán, María Jesús (Hospital Clínic i Provincial de Barcelona) ;
Campins, Magdalena (Hospital Universitari Vall d'Hebron) ;
Portolés, Antonio (Universidad Complutense de Madrid) ;
Lora, David (Universidad Complutense de Madrid) ;
Bermejo, Mercedes (Instituto de Salud Carlos III) ;
Conde, Patricia (Instituto de Salud Carlos III) ;
Hernández-Gutierrez, Lourdes (Instituto de Salud Carlos III) ;
Carcas, Antonio (Hospital Universitario La Paz) ;
Arana-Arri, Eunate (Hospital Universitario Cruces) ;
Tortajada, Marta (Hospital Clínic i Provincial de Barcelona) ;
Fuentes Camps, Inmaculada (Hospital Universitari Vall d'Hebron) ;
Ascaso, Ana (Hospital Clínico San Carlos) ;
García-Morales, María Teresa (Universidad Complutense de Madrid) ;
Erick de la Torre-Tarazona, Humberto (Instituto de Salud Carlos III) ;
Arribas, José-Ramón (Hospital Universitario La Paz) ;
Imaz-Ayo, Natale (Hospital Universitario Cruces) ;
Mellado-Pau, Eugènia (Hospital Clínic i Provincial de Barcelona) ;
Agustí Escasany, M. Antònia (Hospital Universitari Vall d'Hebron) ;
Pérez-Ingidua, Carla (Hospital Clínico San Carlos) ;
Gómez de la Cámara, Agustín (Universidad Complutense de Madrid) ;
Ochando, Jordi (Instituto de Salud Carlos III) ;
Belda-Iniesta, Cristobal (Instituto de Salud Carlos III) ;
Frías, Jesús (Hospital Universitario La Paz) ;
Alcami, Jose (Instituto de Salud Carlos III) ;
Pérez-Olmeda, Mayte (Instituto de Salud Carlos III) ;
Universitat Autònoma de Barcelona
The CombiVacS study was designed to assess immunogenicity and reactogenicity of the heterologous ChAdOx1-S/BNT162b2 combination, and 14-day results showed a strong immune response. The present secondary analysis addresses the evolution of humoral and cellular response up to day 180. [...]
2022 -  10.1016/j.eclinm.2022.101529
EClinicalMedicine, Vol. 50 (july 2022)
|
|
|
2.
|
|
10 p, 456.1 KB |
Reactogenicity to the mRNA-1273 Booster According to Previous mRNA COVID-19 Vaccination
/
Parés-Badell, Oleguer (Hospital Universitari Vall d'Hebron) ;
Zules-Oña, Ricardo (Hospital Universitari Vall d'Hebron) ;
Armadans-Gil, Lluis (Hospital Universitari Vall d'Hebron) ;
Pinós Tella, Laia (Hospital Universitari Vall d'Hebron) ;
Borras Bermejo, Blanca (Hospital Universitari Vall d'Hebron) ;
Otero, Susana (Hospital Universitari Vall d'Hebron) ;
Rodrigo-Pendás, José Ángel (Hospital Universitari Vall d'Hebron) ;
Vivet-Escalé, Martí (Hospital Universitari Vall d'Hebron) ;
Cossio, Yolima (Hospital Universitari Vall d'Hebron) ;
Agustí Escasany, M. Antònia (Hospital Universitari Vall d'Hebron) ;
Aguilera, Cristina (Hospital Universitari Vall d'Hebron) ;
Campins Martí, Magda (Hospital Universitari Vall d'Hebron) ;
Martínez Gómez, Xavier (Hospital Universitari Vall d'Hebron) ;
Universitat Autònoma de Barcelona
The objective of this study was to assess the local and systemic adverse reactions after the administration of a COVID-19 mRNA-1273 booster between December 2021 and February 2022 by comparing the type of mRNA vaccine used as primary series (mRNA-1273 or BNT162b2) and homologous versus heterologous booster in health care workers (HCW). [...]
2022 - 10.3390/vaccines10081217
Vaccines, Vol. 10 (july 2022)
|
|
|
3.
|
|
11 p, 274.2 KB |
Safety of Drugs Used during the First Wave of COVID-19 : A Hospital-Registry-Based Study
/
Aguilera, Cristina (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Danés Carreras, Immaculada (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ;
Guillén, Elena (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ;
Vimes, Alba (Hospital Universitari Vall d'Hebron) ;
Bosch Ferrer, Montserrat (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Cereza García, Gloria (Hospital Universitari Vall d'Hebron) ;
Sánchez-Montalvá, Adrián (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Campos Varela, Isabel (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas) ;
Miarons, Marta (Hospital Universitari Vall d'Hebron) ;
Mestre Torres, Jaume (Hospital Universitari Vall d'Hebron) ;
Agustí Escasany, M. Antònia (Hospital Universitari Vall d'Hebron. Institut de Recerca)
The emergency of the coronavirus disease 2019 (COVID-19) pandemic led to the off-label use of drugs without data on their toxicity profiles in patients with COVID-19, or on their concomitant use. Patients included in the COVID-19 Patient Registry of a tertiary hospital during the first wave were analyzed to evaluate the adverse drug reactions (ADRs) with the selected treatments. [...]
2022 - 10.3390/diagnostics12071612
Diagnostics, Vol. 12 Núm. 7 (july 2022) , p. 1612
|
|
|
4.
|
|
10 p, 253.6 KB |
Spontaneously reported adverse drug reactions and their description in hospital discharge reports : a retrospective study
/
Aguilera, Cristina (Hospital Universitari Vall d'Hebron) ;
Agustí Escasany, M. Antònia (Hospital Universitari Vall d'Hebron) ;
Pérez, Eulàlia (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ;
Gracia, Rosa Maria (Hospital Universitari Vall d'Hebron) ;
Diogène Fadini, Eduard (Hospital Universitari Vall d'Hebron) ;
Danés Carreras, Immaculada (Hospital Universitari Vall d'Hebron)
The inclusion of spontaneously reported adverse drug reactions (ADRs) in hospital discharge reports was examined, in addition to the factors associated with their inclusion, the resulting therapeutic decisions, and any recommendations made upon patient discharge regarding the suspected offending drugs. [...]
2021 - 10.3390/jcm10153293
Journal of clinical medicine, Vol. 10 Núm. 15 (january 2021) , p. 3293
|
|
|
5.
|
|
|
6.
|
|
9 p, 611.2 KB |
Adverse Reactions to Drugs of Special Interest in a Pediatric Oncohematology Service
/
Amaro-Hosey, Kristopher (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ;
Danés Carreras, Immaculada (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Vendrell Bosch, Lourdes (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Alonso, Laura (Vall d'Hebron Institut d'Oncologia) ;
Renedo-Miró, Berta (Hospital Universitari Vall d'Hebron) ;
Gros, Luis (Vall d'Hebron Institut d'Oncologia) ;
Vidal Guitart, Xavier (Hospital Universitari Vall d'Hebron) ;
Cereza García, Gloria (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ;
Agustí Escasany, M. Antònia (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Introduction: Drugs used in oncological diseases are frequently related to adverse drug reactions (ADR). Few studies have analyzed the toxicity of cancer treatments in children in real practice. Methods: An observational, longitudinal and prospective study has been carried out in an Oncohematology Service of a tertiary hospital. [...]
2021 - 10.3389/fphar.2021.670945
Frontiers in Pharmacology, Vol. 12 (may 2021)
|
|
|
7.
|
|
13 p, 423.1 KB |
Off-label use of rituximab in patients with different types of nephropathies in a tertiary hospital : a retrospective study
/
Sans-Pola, Carla (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Agustí Escasany, M. Antònia (Maria Antònia) (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Bosch Gil, Josep Àngel (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Danés Carreras, Immaculada (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ;
Alerany, Carmen (Hospital Universitari Vall d'Hebron) ;
Agraz Pamplona, Irene (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Off-label use of rituximab is commonly requested for patients with resistant nephropathies. The outcomes and tolerability of rituximab in adult patients with nephropathy treated at our hospital (from 2013 to 2018) were described. [...]
2021 - 10.3390/jcm10214941
Journal of clinical medicine, Vol. 10 Núm. 21 (november 2021) , p. 4941
|
|
|
8.
|
|
13 p, 705.8 KB |
Current landscape of clinical development and approval of advanced therapies
/
Iglesias-Lopez, Carolina (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ;
Agustí Escasany, M. Antònia (Hospital Universitari Vall d'Hebron) ;
Vallano, Antoni (Servei Català de la Salut) ;
Obach, Mercè (Servei Català de la Salut)
Advanced therapy medicinal products (ATMPs) are innovative therapies that mainly target orphan diseases and high unmet medical needs. The uncertainty about the product's benefit-risk balance at the time of approval, the limitations of nonclinical development, and the complex quality aspects of those highly individualized advanced therapies are playing a key role in the clinical development, approval, and post-marketing setting for these therapies. [...]
2021 - 10.1016/j.omtm.2021.11.003
Molecular Therapy. Methods & Clinical Development, vol.23 (november 2021) p. 606-618
|
|
|
9.
|
|
14 p, 7.7 MB |
Regulatory framework for advanced therapy medicinal products in Europe and United States
/
Iglesias-Lopez, Carolina (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ;
Agustí Escasany, M. Antònia (Maria Antònia) (Hospital Universitari Vall d'Hebron) ;
Obach, Mercè ;
Vallano, A. (Servei Català de la Salut)
Advanced therapy medicinal products (ATMPs) are a fast-growing field of innovative therapies. The European Union (EU) and the United States (US) are fostering their development. For both regions, ATMPs fall under the regulatory framework of biological products, which determines the legal basis for their development. [...]
2019 - 10.3389/fphar.2019.00921
Frontiers in Pharmacology, Vol. 10 Núm. JULY (2019) , p. 921
|
|
|
10.
|
|
9 p, 929.7 KB |
Reimbursement status and recommendations related to orphan drugs in European countries
/
Stawowczyk, E. (University of Bielsko-Biala. Faculty of Health Sciences) ;
Malinowski, K. P. (Jagiellonian University Medical College) ;
Kawalec, P. (Jagiellonian University Medical College) ;
Bobiński, R. (Jagiellonian University Medical College) ;
Siwiec, J. (Jagiellonian University Medical College) ;
Panteli, D. (European Observatory on Health Systems and Policies) ;
Eckhardt, H. (European Observatory on Health Systems and Policies) ;
Simoens, Steven (KU Leuven. Department of Pharmaceutical and Pharmacological Sciences) ;
Agustí Escasany, M. Antònia (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ;
Dooms, M. (University Hospitals Leuven (Bèlgica)) ;
Pilc, A. (Polish Academy of Sciences. Institute of Pharmacology)
Objective: To review the reimbursement recommendations issued by selected European health technology assessment agencies for orphan drugs and the reimbursement status of these drugs; to assess the relationship between the type of recommendation and reimbursement status. [...]
2019 - 10.3389/fphar.2019.01279
Frontiers in Pharmacology, Vol. 10 (2019), p. 1279
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
